2025 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Authorities are planning a major digitization effort covering the whole value chain, but AI evaluation is still at an early stage.
Biopharma experts including Nobel Laureate Professor Jack Szostak share their views on emerging innovation ecosystems and how India can get it right as it seeks to shift gears in R&D. Panelists noted that VC investments can be a mixed bag, called for regulatory vision that ensures safety alongside accelerated pathways like the LPAD in the US and also ‘open” AI platforms.
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.
